ESTA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 2.96%, SMA50 -0.59%, SMA200 40.52%). The stock’s 14-day RSI is 51.9 (neutral), while the ATR of 3.76 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.16% below its high and over 161.76% above its low. Average 10-day trading volume of 384.43 thousand shares is below the 3-month average of 447.03 thousand, indicating normal recent market interest.

Establishment Labs Holdings Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $64.84. This means the shares are trading above this model’s fair value.

Establishment Labs Holdings Inc. has 28.97 million shares outstanding. The public float is 16.95 million shares, elevated short interest at 24.14% of float. This equals 4.76 million shares. The short ratio is 14.57 days. Institutional investors hold 117.35% of the float. Insiders own 10.74%. Wild Jason G. holds 3.19 million shares, JW Asset Management, LLC has 3.06 million shares and SCHUTTER EDWARD J has 298.56 thousand shares. Over the past six months, insider transactions show net selling. They sold 22.03 thousand shares across 4 transactions.

Establishment Labs Holdings Inc. (NASDAQ:ESTA) closed at $69.51 USD, gaining $0.72 (1.05%) from the previous close of $68.79. The stock is currently mid-range between its 52-week high and low $26.56 and $78.24. With a market capitalization of about $2.02 billion, Establishment Labs Holdings Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 476.39 thousand shares, volume is running light vs its 52-week average. Headquartered in Alajuela, None, Establishment Labs Holdings Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Fillipo Peter Caldini, the company employs approximately 1,034 people and listed since July 19, 2018. Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery.

Establishment Labs Holdings Inc. generated EPS of -$2.85 over the past year. Five-year average earnings growth is -10.09%. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.22. Next year's EPS is expected at $39.64. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 10 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $90.00 to $47.00. The high target offers 29.48% upside. The low target suggests -32.38% downside. The mean target is $71.68. This offers 3.12% upside. Establishment Labs Holdings Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -29.63%. The prior quarter beat by 5.56%. Over the last six quarters, Apple has recorded several small beats. These include 19.23% in August 06, 2024.

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares are down -11.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Establishment Labs Holdings Inc. trading at a premium to the broader market with a P/E of -24.85. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $69.90, suggesting 0.56% upside. Our AI forecast model points to short-term strength (1.67% over two weeks), a medium-term rise (55.29% over three months), and a longer-term loss (-7.93% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Establishment Labs Holdings Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.67%, with price expected at $70.67 by February 20, 2026, within a range of $68.24 to $73.29 3-Month Outlook: Projected rise of 55.29%, reaching $107.94 by May 07, 2026, with a range of $106.77 to $109.42. 1-Year Outlook: Projected loss of -7.93%, with price at $64.00 by February 05, 2027, within a range of $58.23 to $68.96.

Establishment Labs Holdings Inc. trades at a P/E ratio of -24.85, slightly below the S&P 500 average, with a price-to-sales ratio of 10.59 and a price-to-book ratio of 126.0 reflecting a rich premium to book value. The P/FCF stands at -26.09, also below market averages. Compared to sector medians, Establishment Labs Holdings Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.